Completed PHASE1 INTERVENTIONAL 6-arm NCT01103830

Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers

Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Sponsor: Medicines for Malaria Venture

Conditions Malaria, Falciparum

Interventions Eurartesim™ Placebo and finally Moxifloxacin Riamet®

Updated 5 times since 2017 Last updated: Jun 16, 2011 Started: Feb 28, 2010 Primary completion: Aug 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malaria, Falciparum, this trial is completed. The trial is conducted by Medicines for Malaria Venture and has accumulated 5 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medicines for Malaria Venture
sigma-tau i.f.r. S.p.A.

Data source: sigma-tau i.f.r. S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France